MedTrace Logo

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

NCT04005807 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-06-18

No results posted yet for this study

Summary

This is single center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of BPN-14967 in healthy adult subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BPN-14967

BPN-14967 oral capsules

DRUG

Placebo

Oral capsules

Sponsors & Collaborators

  • Belite Bio, Inc

    lead INDUSTRY

Principal Investigators

  • Konstantin Petrukhin, PhD · Professor of Ophthalmic Science, Department of Ophthalmology, Columbia University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2019-12-20
Completion
2019-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04005807 on ClinicalTrials.gov